Kristen Cohen serves as the Director of Clinical Biomarkers for Latent Viruses and Global Health at Moderna, where she plays a pivotal role in shaping biomarker strategies for vaccine programs spanning from early to late phases. With her extensive background as a translational immunologist, Kristen...
Kristen Cohen serves as the Director of Clinical Biomarkers for Latent Viruses and Global Health at Moderna, where she plays a pivotal role in shaping biomarker strategies for vaccine programs spanning from early to late phases. With her extensive background as a translational immunologist, Kristen is adept at navigating the complexities of human immunology, particularly in the context of infectious diseases and vaccination. Her leadership is instrumental in managing a team of biomarker leads dedicated to advancing the Latent Virus and Global Public Health portfolios, ensuring that innovative diagnostic, virologic, and immunologic assays are meticulously selected and validated.
Kristen's expertise in complex assay development and validation, particularly with high-dimension flow cytometry, positions her as a key contributor to Moderna's mission of addressing global health challenges. Her experience conducting translational research in resource-limited settings, such as Port-au-Prince, Haiti, and Durban, South Africa, has equipped her with unique insights into the practical applications of clinical trials and program development in diverse environments. This background not only enhances her ability to influence others within the organization but also fosters a collaborative atmosphere that motivates her team to excel.
Under her oversight, the selection and validation of assays are conducted with a keen understanding of regulatory requirements, including FDA validation processes. Kristen's skills in organizational dynamics and her strategic approach to team motivation ensure that her cross-functional teams operate effectively, driving forward the development of vaccines that can make a significant impact on public health. Her commitment to advancing the field of immunology and infectious diseases is evident in her work, making her a vital asset to Moderna and the broader scientific community.
